Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years.

Using inverse probability weights, an adjusted mITT analysis on these 129 patients revealed a nonsignificant trend toward improved survival in the lomustine/temozolomide arm (HR: 0.74, 95%CI: 0.47-1.17) and no significant difference in progression-free survival (HR: 0.99, 95%CI 0.47-1.44) The findings of these studies are thought-provoking and provide evidence to suggest that the combination therapy of lomustine and temozolomide may enhance survival rates when compared to standard temozolomide treatment in a specific subgroup of younger, healthy patients with MGMT-methylated glioblastoma.

also in 5,406 other papers